{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:03:04Z","timestamp":1792508584101,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s15010-023-02039-2","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T18:02:34Z","timestamp":1681927354000},"page":"1577-1581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab"],"prefix":"10.1007","volume":"51","author":[{"given":"Erica","family":"Franceschini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariachiara","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Todisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Dolci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bettelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Meschiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea.","family":"Bedini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Fregni-Serpini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Grottola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Guaraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Pecorari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Sarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Luppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Federico","family":"Perno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mussini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"key":"2039_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41591-020-01202-8","volume":"27","author":"P Brodin","year":"2021","unstructured":"Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021;27:28\u201333. https:\/\/doi.org\/10.1038\/s41591-020-01202-8.","journal-title":"Nat Med"},{"key":"2039_CR2","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s15010-022-01869-w","volume":"50","author":"A Oliva","year":"2022","unstructured":"Oliva A, Curtolo A, Volpicelli L, Cancelli F, Borrazzo C, Cogliati Dezza F, et al. Clinical course of Coronavirus Disease-19 in patients with haematological malignancies is characterized by a longer time to respiratory deterioration compared to non-haematological ones: results from a case-control study. Infection. 2022;50:1373\u201382. https:\/\/doi.org\/10.1007\/s15010-022-01869-w.","journal-title":"Infection"},{"key":"2039_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/infdis\/jiaa666","volume":"223","author":"JH Baang","year":"2021","unstructured":"Baang JH, Smith C, Mirabelli C, Valesano AL, Manthei DM, Bachman MA, et al. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. J Infect Dis. 2021;223:23\u20137. https:\/\/doi.org\/10.1093\/infdis\/jiaa666.","journal-title":"J Infect Dis"},{"key":"2039_CR4","doi-asserted-by":"publisher","first-page":"ofab217","DOI":"10.1093\/ofid\/ofab217","volume":"8","author":"C Sepulcri","year":"2021","unstructured":"Sepulcri C, Dentone C, Mikulska M, Bruzzone B, Lai A, Fenoglio D, et al. The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient\u2014a case study. Open Forum Infect Dis. 2021;8:ofab217. https:\/\/doi.org\/10.1093\/ofid\/ofab217.","journal-title":"Open Forum Infect Dis"},{"key":"2039_CR5","doi-asserted-by":"publisher","first-page":"e068632","DOI":"10.1136\/bmj-2021-068632","volume":"376","author":"ARYB Lee","year":"2022","unstructured":"Lee ARYB, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376:e068632. https:\/\/doi.org\/10.1136\/bmj-2021-068632.","journal-title":"BMJ"},{"key":"2039_CR6","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/bloodadvances.2021006917","volume":"6","author":"S Haggenburg","year":"2022","unstructured":"Haggenburg S, Lissenberg-Witte BI, van Binnendijk RS, den Hartog G, Bhoekhan MS, Haverkate NJE, et al. Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients. Blood Adv. 2022;6:1537\u201346. https:\/\/doi.org\/10.1182\/bloodadvances.2021006917.","journal-title":"Blood Adv"},{"key":"2039_CR7","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3109\/10428194.2015.1110748","volume":"57","author":"A Gafter-Gvili","year":"2016","unstructured":"Gafter-Gvili A, Polliack A. Bendamustine associated immune suppression and infections during therapy of hematological malignancies. Leuk Lymphoma. 2016;57:512\u20139. https:\/\/doi.org\/10.3109\/10428194.2015.1110748.","journal-title":"Leuk Lymphoma"},{"key":"2039_CR8","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.2217\/fon-2022-0112","volume":"18","author":"A Davies","year":"2022","unstructured":"Davies A, Kater AP, Sharman JP, Stilgenbauer S, Vitolo U, Klein C, et al. Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review. Future Oncol. 2022;18:2943\u201366. https:\/\/doi.org\/10.2217\/fon-2022-0112.","journal-title":"Future Oncol"},{"key":"2039_CR9","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles G, Barrett M, Fo\u00e0 R, Maurer J, O\u2019Brien S, Valente N, et al. Rituximab in B-Cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34:2232\u201373. https:\/\/doi.org\/10.1007\/s12325-017-0612-x.","journal-title":"Adv Ther"},{"key":"2039_CR10","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s10147-021-01863-6","volume":"26","author":"GS Erdal","year":"2021","unstructured":"Erdal GS, Polat O, Erdem GU, Korkusuz R, Hindilerden F, Yilmaz M, et al. The mortality rate of COVID-19 was high in cancer patients: a retrospective single-center study. Int J Clin Oncol. 2021;26:826\u201334. https:\/\/doi.org\/10.1007\/s10147-021-01863-6.","journal-title":"Int J Clin Oncol"},{"key":"2039_CR11","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/s41591-020-0979-0","volume":"26","author":"EV Robilotti","year":"2020","unstructured":"Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020;26:1218\u201323. https:\/\/doi.org\/10.1038\/s41591-020-0979-0.","journal-title":"Nat Med"},{"key":"2039_CR12","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1182\/blood.2020008824","volume":"136","author":"A Vijenthira","year":"2020","unstructured":"Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881\u201392. https:\/\/doi.org\/10.1182\/blood.2020008824.","journal-title":"Blood"},{"key":"2039_CR13","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1080\/10428194.2021.1957877","volume":"62","author":"D Re","year":"2021","unstructured":"Re D, Barri\u00e8re J, Chamorey E, Delforge M, Gastaud L, Petit E, et al. Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies. Leuk Lymphoma. 2021;62:3308\u201310. https:\/\/doi.org\/10.1080\/10428194.2021.1957877.","journal-title":"Leuk Lymphoma"},{"key":"2039_CR14","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41375-021-01418-8","volume":"36","author":"F Marchesi","year":"2022","unstructured":"Marchesi F, Pimpinelli F, Giannarelli D, Ronchetti L, Papa E, Falcucci P, et al. Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin\u2019s lymphomas. Leukemia. 2022;36:588\u201390. https:\/\/doi.org\/10.1038\/s41375-021-01418-8.","journal-title":"Leukemia"},{"key":"2039_CR15","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S2213-2600(22)00180-1","volume":"10","author":"H Montgomery","year":"2022","unstructured":"Montgomery H, Hobbs FDR, Padilla F, Arbetter D, Templeton A, Seegobin S, et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022;10:985\u201396. https:\/\/doi.org\/10.1016\/S2213-2600(22)00180-1.","journal-title":"Lancet Respir Med"},{"key":"2039_CR16","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022;386:1397\u2013408. https:\/\/doi.org\/10.1056\/NEJMoa2118542.","journal-title":"N Engl J Med"},{"key":"2039_CR17","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1093\/infdis\/jiaa446","volume":"222","author":"M Helleberg","year":"2020","unstructured":"Helleberg M, Niemann CU, Moestrup KS, Kirk O, Lebech A-M, Lane C, et al. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J Infect Dis. 2020;222:1103\u20137. https:\/\/doi.org\/10.1093\/infdis\/jiaa446.","journal-title":"J Infect Dis"},{"key":"2039_CR18","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ijid.2020.12.050","volume":"104","author":"D Camprub\u00ed","year":"2021","unstructured":"Camprub\u00ed D, Gaya A, Marcos MA, Mart\u00ed-Soler H, Soriano A, Mosquera MDM, et al. Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir. Int J Infect Dis. 2021;104:379\u201381. https:\/\/doi.org\/10.1016\/j.ijid.2020.12.050.","journal-title":"Int J Infect Dis"},{"key":"2039_CR19","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/bjh.18315","volume":"198","author":"T Shafat","year":"2022","unstructured":"Shafat T, Grupel D, Porges T, Levi I, Yagel Y, Nesher L. Treatment with obinutuzumab leads to worse outcomes in haematological patients diagnosed with Omicron variant COVID-19. Br J Haematol. 2022;198:826\u20139. https:\/\/doi.org\/10.1111\/bjh.18315.","journal-title":"Br J Haematol"},{"key":"2039_CR20","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/OP.20.00241","volume":"16","author":"MEM Percival","year":"2020","unstructured":"Percival MEM, Lynch RC, Halpern AB, Shadman M, Cassaday RD, Ujjani C, et al. Considerations for managing patients with hematologic malignancy during the COVID-19 pandemic: the seattle strategy. JCO Oncol Pract. 2020;16:571\u20138. https:\/\/doi.org\/10.1200\/OP.20.00241.","journal-title":"JCO Oncol Pract"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-023-02039-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-023-02039-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-023-02039-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T09:06:10Z","timestamp":1696237570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-023-02039-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2039"],"URL":"https:\/\/doi.org\/10.1007\/s15010-023-02039-2","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]},"assertion":[{"value":"6 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}